One year in review
Behçet's syndrome: one year in review 2023
G. Hatemi1, E. Seyahi2, I. Fresko3, R. Talarico4, D. Uçar5, V. Hamuryudan6
- Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Division of Ophthalmology, Istanbul University-Cerrahpasa, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey. vhamuryudan@yahoo.com
CER17059
2023 Vol.41, N°10
PI 1945, PF 1954
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 37877363 [PubMed]
Received: 14/08/2023
Accepted : 21/09/2023
In Press: 10/10/2023
Published: 30/10/2023
Abstract
This critical review of studies on Behçet’s syndrome published during 2022 includes studies on epidemiology, patients’ perspective, pathogenesis, diagnosis, clinical features and management. Studies on pathogenesis included potential biomarkers mostly related to macrophages, neutrophil and cytokine balance, new GWAS and polymorphism studies, and studies on miRNAs and long non-coding RNAs. Clinical studies showed that application of pneumococcal vaccine to the prick site increased the sensitivity and specificity of the pathergy test and the prevalence of AA amyloidosis had decreased over the years. Studies on management indicated that more data are needed to understand the effect of apremilast on BS manifestations other than oral ulcers, and new BS manifestations may develop during treatment with infliximab. Other biologics and Jak inhibitors might be an option for patients who are refractory to TNF-α inhibitors. Moreover, endovascular repair of arterial aneurysms might be an alternative to open surgery.
